Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - STEMLINE THERAPEUTICS INCtm2031081d1_ex32-2.htm
EX-32.1 - EXHIBIT 32.1 - STEMLINE THERAPEUTICS INCtm2031081d1_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - STEMLINE THERAPEUTICS INCtm2031081d1_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - STEMLINE THERAPEUTICS INCtm2031081d1_ex31-1.htm
EX-21.1 - EXHIBIT 21.1 - STEMLINE THERAPEUTICS INCtm2031081d1_ex21-1.htm
EX-4.3 - EXHIBIT 4.3 - STEMLINE THERAPEUTICS INCtm2031081d1_ex4-3.htm
10-K - FORM 10-K - STEMLINE THERAPEUTICS INCtm2031081-1_10k.htm

 

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

We consent to the incorporation by reference in the following Registration Statements:

 

(1)Registration Statement (Form S-8 No. 333-188115) pertaining to Stemline Therapeutics, Inc. 2012 Equity Incentive Plan and Stemline Therapeutics, Inc. Amended and Restated 2004 Employee, Director and Consultant Stock Plan,

 

(2)Registration Statement (Form S-8 No. 333-206303) pertaining to Stemline Therapeutics, Inc. 2015 Employee Stock Purchase Plan,

 

(3)Registration Statements (Form S-8 No. 333-211784, Form S-8 No. 333-219796, Form S-8 No. 333-226049, and, Form S-8 No. 333-232445) pertaining to Stemline Therapeutics, Inc. 2016 Equity Incentive Plan,

 

(4)Registration Statement (Form S-3 No. 333-219794) of Stemline Therapeutics, Inc., and

 

(5)Registration Statement (Form S-3 No. 333-230341) of Stemline Therapeutics, Inc.;

 

 

of our reports dated March 16, 2020, with respect to the financial statements of Stemline Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Stemline Therapeutics, Inc. included in this Annual Report (Form 10-K) of Stemline Therapeutics, Inc. for the year ended December 31, 2019.

 

/s/ Ernst & Young LLP

 

Stamford, Connecticut

March 16, 2020